Spyre Therapeutics director Jeffrey W. Albers disposes of USD 2.39 million in common shares - SYRE News | RalliesSpyre Therapeutics director Jeffrey W. Albers disposes of USD 2.39 million in common shares
S
SYRE• Director and related entity sell Spyre shares
- Spyre Therapeutics director Jeffrey W. Albers exercised stock options to buy 5,000 common shares at USD 10.39 on Aug. 7.
- Albers sold 5,000 shares at a weighted average USD 104.47 on Aug. 7, reducing his direct stake to zero shares.
- Sessions LLC, an entity tied to Albers, sold 18,000 shares at weighted average prices near USD 104.38–104.68 on Aug. 7.
- Sessions LLC reported 9,360 shares of common stock remaining after the sales.
MMI
•
